成都普瑞法科技开发有限公司欢迎您!
ISO ISO
CNAS CNAS
高新技术企业 高新技术企业
USP USP
知识产权管理体系认证证书 知识产权管理体系认证证书

文献列表

专业生产定制高含量植提产品和中药成分

您当前的位置:
期刊名:Neuropharmacology
文献编号:
文献地址: http://www.sciencedirect.com/science/article/pii/S0028390817300783
发表日期:1 May 2017
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in substantia nigra (SN). Our previous study demonstrated Kukoamine A to exhibit strong neuroprotective effects through anti-oxidative stress, anti-inflammation, anti-excitoxicity. In the present study, MPP+ and MPTP-induced PD models of cell and animal were used to investigate the effects of KuA on PD. Our results demonstrated that KuA ameliorated cell loss and mitochondrial membrane potential (MMP) loss, and inhibited Bax/Bcl-2 ratio and MAPKs family that were induced by MPP+. In addition, animal experiments showed that KuA improved the motor function and neuronal activity, and increased the positive cells of tyrosine hydroxylase (TH) both in substantia nigra (SN) and striatum (Str). Moreover, KuA could decrease the expression of α-synuclein in brain. Finally, KuA exerted apparent autophagy enhancement both in vitro and in vivo. In conclusion, KuA protected against neurotoxin-induced PD due to the apoptosis inhibition and autophagy enhancement, suggesting that KuA treatment might represent a neuroprotective treatment for PD.


... All the results indicated that KuA may be a promising agent of PD treatment. 2. Materials and methods. 2.1. Chemicals and reagents. Kukoamine A (>98%) was purchased from Chengdu Biopurify Phytochemicals Ltd. (China) (Dissolved in 0.9% NaCl). ...
 
相关产品